Patients, Immunocompromised

The Infectious Disease Society of America suggests that immunocompromised patients take the COVID-19 prevention drug pemivibart as pre-exposure prophylaxis to help prevent severe COVID-19, according to new guidelines.

In new guidance, the Infectious Diseases Society of America suggested that immunocompromised patients take the monoclonal antibody pemivibart as pre-exposure prophylaxis to prevent severe COVID-19.

Nicotinamide therapy was not effective in lowering the rates of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients, according to a phase 3 trial.

Patients on hemodialysis who received the high-dose trivalent inactivated influenza vaccine showed a stronger seroresponse than those who received other vaccines, according to data published the American Journal of Kidney Diseases.

Suboptimal COVID-19 vaccination rates in the general population and poor vaccine response in the immunocompromised have forced the rheumatology community to look beyond the specialty in trying to protect vulnerable individuals from the virus.

In certain settings.

Sepsis is a leading cause of preventable death across the globe, and patients with cancer have a 10 times higher likelihood of developing this life-threatening condition than those without cancer.

Adults with inflammatory bowel disease produced strong antibody responses to messenger RNA COVID-19 vaccines, according to findings published in Annals of Internal Medicine.

A CDC advisory panel voted unanimously in favor of recommending a third dose of the COVID-19 vaccine in patients who are moderately or severely immunocompromised, according to an American College of Rheumatology press release.